Literature DB >> 17117015

Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.

Jianqing Xu1, Li Ren, Xianggang Huang, Chao Qiu, Yong Liu, Ying Liu, Yiming Shao.   

Abstract

BACKGROUND: The effort to develop an effective preventive vaccine against HIV-1 infection is challenged by the wide genetic diversity of HIV-1 among different isolates.
OBJECTIVES: To explore a new vaccination strategy by using heterologous HIV immunogens derived from different clades for sequential priming and boosting.
METHODS: HIV Env and Gag immunogens derived from Thailand B (B'), C/B' recombinant and A/E recombinant were selected as these three clades account for 29%, 45% and 15% of HIV-1 prevalence in China, respectively. Three humanized fusion genes of env and gag derived from those three clades were synthesized and inserted into DNA and recombinant Tiantan vaccinia vectors as model vaccines. C57BL/6 and Balb/c mice were used as animal model. Peptides spanning the entire Env and Gag were used as stimuli and Elispot assay was used to assess the T cell immunity.
RESULTS: Sequential priming and boosting was observed with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes, whereas a single vaccine derived from one clade or the mixture of multiple vaccines from different clades primarily raised T cells against less conservative or non-conservative epitopes.
CONCLUSIONS: This is the first demonstration of a practical strategy to raise immune responses against conserved epitopes. This strategy has important implications for vaccine development against HIV and other pathogens that have high genetic diversity, such as influenza.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117015     DOI: 10.1097/QAD.0b013e328010ad0c

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Authors:  Eric Sandström; Charlotta Nilsson; Bo Hejdeman; Andreas Bråve; Göran Bratt; Merlin Robb; Josephine Cox; Thomas Vancott; Mary Marovich; Richard Stout; Said Aboud; Muhammad Bakari; Kisali Pallangyo; Karl Ljungberg; Bernard Moss; Patricia Earl; Nelson Michael; Deborah Birx; Fred Mhalu; Britta Wahren; Gunnel Biberfeld
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

2.  Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

Authors:  Yanmin Wan; Lan Wu; Lianxing Liu; Jianqing Xu; Ying Liu; Yong Liu; Yiming Shao
Journal:  Vaccine       Date:  2007-02-26       Impact factor: 3.641

3.  Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.

Authors:  Charlotte Dubé; Sarah Paris-Robidas; Guadalupe Andreani; Cindy Gutzeit; Marc-André D'Aoust; Brian J Ward; Sonia Trépanier
Journal:  Vaccine       Date:  2022-05-27       Impact factor: 4.169

4.  Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.

Authors:  Patricia L Earl; Catherine Cotter; Bernard Moss; Thomas VanCott; Jeffrey Currier; Leigh Anne Eller; Francine McCutchan; Deborah L Birx; Nelson L Michael; Mary A Marovich; Merlin Robb; Josephine H Cox
Journal:  Vaccine       Date:  2009-08-03       Impact factor: 3.641

5.  A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine.

Authors:  Qinglai Meng; Yuezhi Lin; Jian Ma; Yan Ma; Liping Zhao; Shenwei Li; Kai Yang; Jianhua Zhou; Rongxian Shen; Xiaoyan Zhang; Yiming Shao
Journal:  Viral Immunol       Date:  2012-11-21       Impact factor: 2.257

6.  Immune Signature of Enhanced Functional Avidity CD8+ T Cells in vivo Induced by Vaccinia Vectored Vaccine.

Authors:  Zhidong Hu; Lingyan Zhu; Jing Wang; Yanmin Wan; Songhua Yuan; Jian Chen; Xiangqing Ding; Chenli Qiu; Xiaoyan Zhang; Chao Qiu; Jianqing Xu
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

7.  The average IFN-γ secreting capacity of specific CD8(+) T cells is compromised while increasing copies of a single T cell epitope encoded by DNA vaccine.

Authors:  Yanmin Wan; Jing Wang; Haizhu Zhou; Zhidong Hu; Xiaonan Ren; Jianqing Xu
Journal:  Clin Dev Immunol       Date:  2012-11-01

8.  Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Authors:  Silvia Ratto-Kim; Jeffrey R Currier; Josephine H Cox; Jean-Louis Excler; Anais Valencia-Micolta; Doris Thelian; Vicky Lo; Eddy Sayeed; Victoria R Polonis; Patricia L Earl; Bernard Moss; Merlin L Robb; Nelson L Michael; Jerome H Kim; Mary A Marovich
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

9.  Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine.

Authors:  Lianxing Liu; Chao Qiu; Yang Huang; Jianqing Xu; Yiming Shao
Journal:  Virol Sin       Date:  2013-04-11       Impact factor: 6.947

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.